Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001031 | 1.00 | HTT (0.55) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL3532081 | 1.00 | HTT (0.55) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL24106055 | 0.95 | EPHX1 (0.51) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL1600934 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL2461645 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL598847 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL8613632 | 0.83 | HTT (0.56) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| Pyridine SCHEMBL28149473 | 0.80 | PDPK1 (0.49) | HTTALDH1A1TSHR | |
| SCHEMBL2115700 | 0.80 | HTT (0.63) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL19120324 | 0.79 | ALDH1A1 (0.54) | HTTALDH1A1KMT2AMEN1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3151920-B1 | USE OF INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS IN HIV THERAPY | SANFORD BURNHAM MED RES INST (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250129099-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2025-04-24 | — | — | US | disclosed |
| EP-4426707-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| WO-2023081290-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4143198-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-2925764-B1 | INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS | SANFORD BURNHAM MED RES INST (US) | 2023-03-01 | — | — | EP | disclosed |
| US-7807699-B2 | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2008128121-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
| WO-2007143267-A2 | TREATMENT OF PAIN DISORDERS WITH TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007136921-A2 | SMALL MOLECULE APOPTOSIS PROMOTERS | JOYANT PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007006003-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | SEPRACOR INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129099-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | HTT 3785/4885ALDH1A1 4338/4885KMT2A 3935/4885 |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | HTT 3048/4885ALDH1A1 158/4885KMT2A 1654/4885 |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | HTT 440/4885ALDH1A1 1422/4885KMT2A 2346/4885 |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | HTT 2134/4885ALDH1A1 4556/4885KMT2A 4599/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | HTT 3785/4885ALDH1A1 4338/4885KMT2A 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.